PHMMF (Pharma Mar) Cyclically Adjusted Revenue per Share: $13.19 (As of Mar. 2026)


PHMMF Pharma Mar SA PHMMF
82 GF Score
Price $79.49
GF Value $78.95
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Cyclically Adjusted Revenue per Share?

Pharma Mar PHMMF -25.35% 82 Cyclically Adjusted Revenue per Share is $13.19 as of Mar. 2026. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $78.95 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharma Mar's adjusted revenue per share for the three months ended in Mar. 2026 was $2.866. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $13.19 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pharma Mar's average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharma Mar was 6.30% per year. The lowest was -0.50% per year. And the median was 3.60% per year.

As of today (2026-07-08), Pharma Mar's current stock price is $79.49. Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $13.19. Pharma Mar's Cyclically Adjusted PS Ratio of today is 6.03.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 5.07.


Pharma Mar  (OTCPK:PHMMF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharma Mar's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=79.49/13.19
=6.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 5.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharma Mar Cyclically Adjusted Revenue per Share Related Terms


Pharma Mar Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Cyclically Adjusted Revenue per Share Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.15 11.58 12.43 11.62 13.73

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.40 13.46 12.82 13.73 13.19

PHMMF vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PS Ratio falls into.


PHMMF
82GF Score
Pharma Mar SA PHMMF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Mar's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.866/129.8600*129.8600
=2.866

Current CPI (Mar. 2026) = 129.8600.

Pharma Mar Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.044 100.333 3.940
201609 2.890 99.737 3.763
201612 2.367 101.842 3.018
201703 2.641 100.896 3.399
201706 3.139 101.848 4.002
201709 1.745 101.524 2.232
201712 2.245 102.975 2.831
201803 1.861 102.122 2.366
201806 2.445 104.165 3.048
201809 1.416 103.818 1.771
201812 1.233 104.193 1.537
201903 1.190 103.488 1.493
201906 1.346 104.612 1.671
201909 1.258 103.905 1.572
201912 1.403 105.015 1.735
202003 5.945 103.469 7.461
202006 4.269 104.254 5.318
202009 3.441 103.521 4.317
202012 3.211 104.456 3.992
202103 3.362 104.857 4.164
202106 3.149 107.102 3.818
202109 2.720 107.669 3.281
202112 5.615 111.298 6.551
202203 3.252 115.153 3.667
202206 2.819 118.044 3.101
202209 2.413 117.221 2.673
202212 2.973 117.650 3.282
202303 2.024 118.948 2.210
202306 2.785 120.278 3.007
202309 2.247 121.343 2.405
202312 2.504 121.300 2.681
202403 2.357 122.762 2.493
202406 2.631 124.409 2.746
202409 2.916 123.121 3.076
202412 5.602 124.753 5.831
202503 2.400 125.531 2.483
202506 3.731 127.251 3.808
202509 2.437 126.840 2.495
202512 8.656 128.400 8.754
202603 2.866 129.860 2.866

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $13.19 mean?
Pharma Mar (PHMMF) has a Cyclically Adjusted Revenue per Share of $13.19 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Cyclically Adjusted Revenue per Share too high?
Pharma Mar's current Cyclically Adjusted Revenue per Share is $13.19. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Pharma Mar's Cyclically Adjusted Revenue per Share of $13.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Mar and its competitors. Pharma Mar's current Cyclically Adjusted Revenue per Share is $13.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $78.95, compared to a current price of $79.49 — trading 0.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $13.19. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Cyclically Adjusted Revenue per Share is $13.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (PHMMF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be overvalued. The current stock price of $79.49 is trading 0.7% above its estimated GF Value™ of $78.95. GuruFocus considers Pharma Mar to be Fairly Valued.

Key valuation signals for PHMMF:

  • Cyclically Adjusted Revenue per Share: $13.19
  • GF Value™: $78.95 vs. price of $79.49 (0.7% above fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score

Get the complete analysis for PHMMF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.49
Price
$78.95
GF Value